Fairmount Funds Management LLC: VIRIDIAN THERAPEUTICS INC (VRDN): Quarterly 13F Position History
As of Q1 2026, Fairmount Funds Management LLC reported 3,914,458 shares of VIRIDIAN THERAPEUTICS INC (VRDN), worth $76.6M and representing 5.5% of its 13F equity book. The position first appeared in Q1 2021 and has been disclosed across 21 13F-HR filings in Pactolio's tracked window.
- 3,914,458Shares Held (Latest Filing)
- $76.6MReported Market Value (Latest Filing)
- 5.5%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$45.3MQuarter-over-Quarter Value Change
- 3,914,458Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 21 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 3,914,458 | 0 | — | $76.6M | 5.5% | $19.6 |
| Q4 2025 | 3,914,458 | +454,545 | +13.1% | $121.8M | 9.3% | $31.1 |
| Q3 2025 | 3,459,913 | 0 | — | $74.7M | 6.7% | $21.6 |
| Q2 2025 | 3,459,913 | +14,100 | +0.4% | $48.4M | 6.3% | $14.0 |
| Q1 2025 | 3,445,813 | 0 | — | $46.4M | 7.2% | $13.5 |
| Q4 2024 | 3,445,813 | 0 | — | $66.1M | 6.6% | $19.2 |
| Q3 2024 | 3,445,813 | +1,600,000 | +86.7% | $78.4M | 6.4% | $22.8 |
| Q2 2024 | 1,845,813 | 0 | — | $24.0M | 2.7% | $13.0 |
| Q1 2024 | 1,845,813 | +476,190 | +34.8% | $32.3M | 3.5% | $17.5 |
| Q4 2023 | 1,369,623 | 0 | — | $29.8M | 3.2% | $21.8 |
| Q3 2023 | 1,369,623 | 0 | — | $21.0M | 2.5% | $15.3 |
| Q2 2023 | 1,369,623 | 0 | — | $32.6M | 4.6% | $23.8 |
| Q1 2023 | 1,369,623 | 0 | — | $34.8M | 6.0% | $25.4 |
| Q4 2022 | 1,369,623 | 0 | — | $40.0M | 6.3% | $29.2 |
| Q3 2022 | 1,369,623 | +425,531 | +45.1% | $28.1M | 5.2% | $20.5 |
| Q2 2022 | 944,092 | 0 | — | $10.9M | 2.5% | $11.6 |
| Q1 2022 | 944,092 | 0 | — | $17.5M | 4.1% | $18.5 |
| Q4 2021 | 944,092 | 0 | — | $18.7M | 6.2% | $19.8 |
| Q3 2021 | 944,092 | +909,000 | +2590.3% | $15.5M | 5.6% | $16.4 |
| Q2 2021 | 35,092 | 0 | — | $642.0K | 0.3% | $18.3 |
| Q1 2021 | 35,092 | — | — | $581.0K | 0.2% | $16.6 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Fairmount Funds Management LLC first disclose a VRDN position in 13F-HR filings?
Fairmount Funds Management LLC first reported VIRIDIAN THERAPEUTICS INC (VRDN) on its 13F-HR filing for the period ending 2021-03-31 (Q1 2021). The position has appeared on 21 reported quarters within Pactolio's tracked window.
What was Fairmount Funds Management LLC's most recent quarter-over-quarter share-count change in VRDN?
Fairmount Funds Management LLC held the same 3,914,458 shares of VRDN between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Fairmount Funds Management LLC's cost basis in VRDN?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.